Siliq / Kyntheum real life data

[Fred]

This study evaluated the effectiveness and safety profile of Siliq / Kyntheum (brodalumab) over a period of 104 weeks in the everyday practice.

Quote:

---

BACKGROUND:
Brodalumab, a fully human IgG2k antibody blocking the receptor of IL17, is characterized by a rapid onset of action with high skin clearance rates in clinical trials. Since setting PASI90/100 or absolute PASI≤3 as treatment goals has become attainable, evaluating effectiveness and safety profile of biologic agents, such as brodalumab, in a real-world setting is essential.

OBJECTIVE:
The aim of this study was to evaluate the effectiveness and safety profile of brodalumab over a period of 104 weeks in the everyday practice. Clinical predictive factors of initial (week 12/16) response to treatment and long-term drug survival were also investigated.

METHODS:
In this monocentric, retrospective study, PASI90/100 and absolute PASI≤1/3 were assessed in 91 patients with moderate-to-severe skin psoriasis under brodalumab at weeks 12/16, 24, 52, and 104 of treatment. At week 12/16, patients with an absolute PASI≤3 were defined as „initial-responders” and ≤1 as “super-responders”. Clinical parameters, such as age, gender, BMI, comorbidities, and previous systemic treatment were assessed in order to predict “super-responders”. Drug survival and its prognostic factors were also evaluated.

RESULTS:
PASI90/100 was reached in 81.1/66.0% at week 12/16. This response rate increased at week 104, where 87.1/80.7% had PASI90/100 and 84.9% had absolute PASI≤1. The presence of > 3 comorbidities, prior treatment with > 2 systemic agents, and obesity tended to be negative predictive factors of “super-response”. Previous exposure to IL17 inhibitors had no impact on both PASI<1 and PASI<3 initial response. One- and two-year drug survival probability was 87.6% and 77.32%, respectively. “Initial responders” and anti-IL17 drug naïve patients had better drug survival. Drug discontinuation occurred in 24.2%, mostly due to secondary failure and arthralgia was the most common adverse event that led to discontinuation.

CONCLUSIONS:
Our study confirms the high effectiveness and good safety profile of brodalumab in the real-world setting.

Source: onlinelibrary.wiley.com

*Early view funding unknown

Kyntheum / Siliq (brodalumab)